US Broker Ratings

Waters Corporation (WAT) Stock Analysis: Navigating a Healthcare Giant with Strong Revenue Growth and Robust Analyst Support

Waters Corporation (NYSE: WAT), a leader in the diagnostics and research industry within the healthcare sector, presents a compelling investment narrative with its robust revenue growth and high analyst interest...

Stryker Corporation (SYK) Stock Analysis: 12.46% Potential Upside in the Medical Device Sector

Stryker Corporation (NYSE: SYK), a titan in the healthcare sector, stands at the forefront of the medical device industry. With a market capitalization of $145.96 billion, this U.S.-based company is..

Agilent Technologies, Inc. (A) Stock Analysis: Navigating Growth with a 19.88% Return on Equity

Agilent Technologies, Inc. (NYSE: A), a prominent player in the healthcare sector specifically within diagnostics and research, continues to draw investor attention with its robust performance metrics and strategic market..

Bristol-Myers Squibb (BMY) Stock Analysis: A 21% Potential Upside in Healthcare Investment

Bristol-Myers Squibb Company (NYSE: BMY), a titan in the healthcare sector, offers intriguing opportunities for investors with its current market position and potential upside. With a market cap of $89.21..

Intuitive Surgical, Inc. (ISRG): Investor Outlook with an 8.74% Upside Potential

Intuitive Surgical, Inc. (NASDAQ: ISRG) continues to capture investor attention with its innovative contributions to the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization..

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Investor Outlook Highlights 25.45% Upside Potential

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a leading player in the biotechnology industry, presents a compelling opportunity for investors, boasting a potential upside of 25.45% according to analyst ratings. With a..

Elevance Health, Inc. (ELV) Stock Analysis: A Stable Player with 13.52% Potential Upside

Elevance Health, Inc. (NYSE: ELV), a prominent player in the healthcare plans industry, offers a robust investment case with a compelling potential upside of 13.52%. This healthcare behemoth, headquartered in..

Cardinal Health, Inc. (CAH) Stock Analysis: Exploring a Potential Upside of 11.94% Amid Strong Buy Ratings

Cardinal Health, Inc. (NYSE: CAH) stands as a formidable player in the healthcare sector, specifically within the medical distribution industry. With a market capitalization of $38.46 billion, this Ohio-based company..

AbbVie Inc. (ABBV) Stock Analysis: Unpacking a $402 Billion Giant with Strong Market Position

AbbVie Inc. (ABBV), a major player in the healthcare sector, stands out with a formidable market capitalization of $402.76 billion, making it one of the giants in the drug manufacturing..

Merck & Company, Inc. (MRK) Stock Analysis: Evaluating a 16.40% Potential Upside for Investors

Merck & Company, Inc. (NYSE: MRK), a stalwart in the healthcare sector, commands a market cap of $218.53 billion and holds a prominent position in the drug manufacturing industry. With..

Astrazeneca PLC (AZN) Stock Analysis: Riding the 11.75% Potential Upside Wave

AstraZeneca PLC (AZN), a towering presence in the biopharmaceutical sector, continues to capture investor attention with its promising growth trajectory and robust pipeline of prescription medicines. With a market capitalization..

Novo Nordisk A/S (NVO) Investor Outlook: Can This Danish Pharma Giant Deliver a 14% Upside?

Novo Nordisk A/S (NYSE: NVO), a titan in the healthcare sector, has been a formidable player in the global pharmaceutical industry for nearly a century. With its headquarters nestled in..

Becton, Dickinson and Company (BDX) Stock Analysis: Evaluating the 12% Upside Potential for Investors

Investors in the healthcare sector often look for stable, growth-oriented companies that can withstand market volatility while delivering consistent returns. Becton, Dickinson and Company (NYSE: BDX) stands as a compelling..

Gilead Sciences, Inc. (GILD): Investor Outlook with a Solid 2.61% Dividend Yield and Strategic Collaborations

Gilead Sciences, Inc. (NASDAQ: GILD) continues to stand as a formidable player in the biopharmaceutical industry, with a robust market capitalization of $150.06 billion. As a leading name in the..

Boston Scientific Corporation (BSX) Stock Analysis: Impressive 24.75% Potential Upside Captures Investor Attention

Boston Scientific Corporation (NYSE: BSX), a titan in the healthcare sector specializing in medical devices, offers a compelling narrative for investors seeking robust growth potential. With a market capitalization of..

MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech with a Potential 265% Upside

In the ever-evolving world of biotechnology, MBX Biosciences, Inc. (NASDAQ: MBX) stands out with a compelling case for investors seeking high-growth opportunities. With a market capitalization of $721.26 million, this..

Standard BioTools Inc. (LAB) Stock Analysis: Uncovering a 28.62% Potential Upside in the Healthcare Sector

Standard BioTools Inc. (NASDAQ: LAB), operating within the Healthcare sector, specifically in the Medical Devices industry, is drawing investor attention with its potential for a 28.62% upside based on analyst..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: A 94.65% Potential Upside in the Healthcare Sector

Organogenesis Holdings Inc. (NASDAQ: ORGO), a leading player in the regenerative medicine space, is capturing the attention of investors with a tantalizing 94.65% potential upside, according to recent analyst ratings...

Verastem, Inc. (VSTM) Stock Analysis: Nearly 100% Upside Potential Amid Biotech Innovation

Verastem, Inc. (NASDAQ: VSTM), a pioneering biopharmaceutical company, presents a compelling case for investors seeking exposure to the biotechnology sector, particularly in the promising field of cancer treatment. With a..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: 59% Potential Upside Fuels Investor Excitement

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is increasingly capturing the attention of savvy investors, thanks to its remarkable growth potential and promising advancements in the biotechnology sector. Focused on the development..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds